IXICO Stock

IXICO EBIT

The EBIT of IXICO (IXI.L) as of Aug 10, 2026 is -2.55 M GBP. In the previous year, EBIT was -2.15 M GBP — a change of 18.57% (lower).

EBIT

-2.55 MGBP

YoY

18.57%

Last updated:

In 2026, IXICO's EBIT was -2.55 M GBP, a 18.57% increase from the -2.15 M GBP EBIT recorded in the previous year.

The IXICO EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M GBP)
Date
EBIT (M GBP)
Jan 1, 2019
0.36 base
Jan 1, 2020
0.86 base
Jan 1, 2021
1.12 base
Jan 1, 2022
0.91 base
Jan 1, 2023
-1.44 base
Jan 1, 2024
-2.15 base
Jan 1, 2025
-2.55 base
Jan 1, 2026 (e)
-2.58 base
YEAREBIT (M GBP)
2026 est -2.58
2025 -2.55
2024 -2.15
2023 -1.44
2022 0.91
2021 1.12
2020 0.86
2019 0.36
2018 -0.80
2017 -1.43
2016 -2.16
2015 -1.14
2014 -1.58
2013 -5.18
2012 -9.30
2011 -8.55
2010 -4.50
2009 -3.97
2008 -2.75
2007 -6.55
2006 -6.62
Access this data via the Eulerpool API

IXICO Revenue

IXICO Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
7.56 M GBP
360,000.00 GBP
430,000.00 GBP
Jan 1, 2020
9.53 M GBP
860,000.00 GBP
950,000.00 GBP
Jan 1, 2021
9.19 M GBP
1.12 M GBP
1.51 M GBP
Jan 1, 2022
8.64 M GBP
910,000.00 GBP
1.03 M GBP
Jan 1, 2023
6.67 M GBP
-1.44 M GBP
-1.18 M GBP
Jan 1, 2024
5.77 M GBP
-2.15 M GBP
-2.00 M GBP
Jan 1, 2025
6.53 M GBP
-2.55 M GBP
-1.65 M GBP
Jan 1, 2026 (e)
7.73 M GBP
-2.58 M GBP
-1.66 M GBP

IXICO Margins

IXICO stock margins

The IXICO margin analysis displays the gross margin, EBIT margin, as well as the profit margin of IXICO. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for IXICO.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
65.34 %
4.76 %
5.69 %
Jan 1, 2020
66.63 %
9.02 %
9.97 %
Jan 1, 2021
65.51 %
12.19 %
16.43 %
Jan 1, 2022
60.65 %
10.53 %
11.92 %
Jan 1, 2023
49.03 %
-21.59 %
-17.69 %
Jan 1, 2024
47.02 %
-37.36 %
-34.70 %
Jan 1, 2025
48.71 %
-39.09 %
-25.27 %
Jan 1, 2026 (e)
48.71 %
-33.33 %
-21.47 %

IXICO Stock analysis

What does IXICO do? IXICO PLC is a leading company in the field of digital biomarker and data services in clinical development. The company was originally founded in London in 2004 and has since had a successful history in neurology and psychiatry research. IXICO's core competency lies in developing and commercially implementing innovative solutions in the field of digital biomarker analysis, data capture, and processing. Through the use of advanced image analysis, structural analysis, and cognitive assessment technologies, IXICO enables effective clinical development of drugs and therapies, particularly in the areas of neurological and psychiatric disorders. IXICO is organized into three main divisions: Digital Healthcare Analytics (DHA), Data Analytics Services (DAS), and Clinical Trial Technology Solutions (CTTS). Each division includes its own products and services tailored to meet the specific requirements and needs of customers. The Digital Healthcare Analytics division focuses on developing biomarker-based clinical software-as-a-service (SaaS) solutions. These are used for monitoring and diagnosing neurological disorders such as Alzheimer's, Parkinson's, and schizophrenia. The solutions developed are tailored to the needs of clinics, research institutions, and biopharmaceutical companies and significantly contribute to the improvement of patient analysis and treatment. The Data Analytics Services division includes a wide range of services for data capture, processing, and analysis. This includes, for example, image and data analysis of clinical data, support for sponsors in data management and study monitoring, as well as consulting and training services. The purpose of this division is to help sponsors work in compliance with regulatory requirements and best practices in the pharmaceutical industry. IXICO's Clinical Trial Technology Solutions division offers a range of technology solutions to support the clinical research of pharmaceutical and biotechnology companies. This includes software solutions such as Neurostatus.net, a neurostatus toolkit for digital assessment of neurological patients, and TrialTracker, a SaaS solution that supports sponsors in the planning and conduct of studies. With its pioneering products and services, IXICO has numerous customers worldwide, including large pharmaceutical and biotech companies. The company also has partnerships with some of the most renowned academic institutions in Europe and North America and is proud to have been part of some of the most significant clinical studies in the field of neurology in recent years. Under the leadership of founder and CEO Derek Hill, IXICO has built an experienced and highly qualified team of scientists and industry experts over the years. The employees come from a variety of disciplines and industries and work closely together to develop innovative solutions and meet customer needs. The company expects to continue successfully focusing on the development of technology-based solutions in clinical research in the future. IXICO is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing IXICO's EBIT

IXICO's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of IXICO's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

IXICO's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in IXICO’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about IXICO stock

EBIT of IXICO is -2.55 M GBP in 2026.

EBIT of IXICO changed from -2.15 M GBP to -2.55 M GBP, representing a 18.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT IXICO since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's GBP is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's IXICO historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — IXICO

All Key Metrics — IXICO